Literature DB >> 26657956

Nicotine-Targeting Nano-Vaccines for Smoking Cessation.

Rajeev I Desai1, Jack Bergman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26657956      PMCID： PMC4677130          DOI： 10.1038/npp.2015.234

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN： 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  6 in total

1.  Effects of the Nanoparticle-Based Vaccine, SEL-068, on Nicotine Discrimination in Squirrel Monkeys.

Authors:  Rajeev I Desai; Jack Bergman
Journal:  Neuropsychopharmacology       Date:  2015-03-06       Impact factor: 7.853

Review 2.  New directions in nicotine vaccine design and use.

Authors:  Paul R Pentel; Mark G LeSage
Journal:  Adv Pharmacol       Date:  2014

Review 3.  Nicotine addiction.

Authors:  Neal L Benowitz
Journal:  N Engl J Med       Date:  2010-06-17       Impact factor: 91.245

4.  Generation of a universal CD4 memory T cell recall peptide effective in humans, mice and non-human primates.

Authors:  Christopher C Fraser; David H Altreuter; Petr Ilyinskii; Lynnelle Pittet; Robert A LaMothe; Mark Keegan; Lloyd Johnston; Takashi Kei Kishimoto
Journal:  Vaccine       Date:  2014-02-26       Impact factor: 3.641

Review 5.  Recognising nicotine: the neurobiological basis of nicotine discrimination.

Authors:  Janice W Smith; Ian P Stolerman
Journal:  Handb Exp Pharmacol       Date:  2009

6.  Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic.

Authors:  D K Hatsukami; D E Jorenby; D Gonzales; N A Rigotti; E D Glover; C A Oncken; D P Tashkin; V I Reus; R C Akhavain; R E F Fahim; P D Kessler; M Niknian; M W Kalnik; S I Rennard
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875
  6 in total
  3 in total

Review 1.  Biologics to treat substance use disorders: Current status and new directions.

Authors:  Marco Pravetoni
Journal:  Hum Vaccin Immunother       Date:  2016-07-21       Impact factor: 3.452

2.  Are therapeutic vaccines an answer to the global problem of drug and alcohol abuse?

Authors:  Dick B S Brashier; Ashok Kumar Sharma; Neha Akhoon
Journal:  Indian J Pharmacol       Date:  2016 Sep-Oct       Impact factor: 1.200

3.  Dose-Response Effect of Antibodies to S100 Protein and Cannabinoid Receptor Type 1 in Released-Active Form in the Light-Dark Test in Mice.

Authors:  Elena V Kardash; Irina A Ertuzun; Gul'nara R Khakimova; Andrey N Kolyadin; Sergey A Tarasov; Stéphanie Wagner; Emile Andriambeloson; Vladimir T Ivashkin; Oleg I Epstein
Journal:  Dose Response       Date:  2018-06-26       Impact factor: 2.658
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.